Skip to Content

Corifollitropin alfa Approval Status

Corifollitropin alfa is a sustained follicular stimulant in development for use in a fertility treatment regimen.

In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for corifollitropin alfa. Merck is evaluating the information provided in the CRL. Corifollitropin alfa is marketed as Elonva in more than 75 countries.

Development Status and FDA Approval Process for corifollitropin alfa

Jul 29, 2014Merck Receives Complete Response Letter from the U.S. FDA for New Drug Application for Corifollitropin Alfa
Sep  9, 2013Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.